Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 49 people enrolled
- Started
- 19 Apr 2021
- Ended
- 23 Jan 2024
- Type of study
- Interventional
- Treatments tested
- nVNS (gammaCore)
- Record updated
- 15 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age 18 years or older at registration
- Diagnosis of gastroparesis as documented by gastric emptying scintigraphy (4-hour emptying after a low-fat meal with any combination of 2- and 4-hour retention of >60% and 10%, respectively), or Chronic Unexplained Nausea and Vomiting (CUNV)
- Ongoing symptoms (i.e. Nausea and vomiting, bloating, and abdominal pain) with a nausea score of 3 or more on the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) scale at baseline (moderate to severe nausea)
- Exclusion of other causes of symptoms such as mechanical gastrointestinal obstruction, uncontrolled esophagitis, peptic ulcer disease, etc. By standard radiographic or endoscopic tests
- Use of the following medications on an as-needed basis: ondansetron, promethazine or prochlorperazine but no more than four times a day
Who cannot take part
- A previous surgery of the upper gastrointestinal tract, including vagotomy
- Previous bilateral or right cervical vagotomy
- Implanted with metal cervical spine hardware or has a metallic implant near the gammaCore stimulation site
- Another active disorder, which could explain symptoms in the opinion of the investigator
- Abnormal baseline ECG (e.g. Second- and third-degree heart block, atrial fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction)
- Currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant
- History of carotid endarterectomy or vascular neck surgery on the right side
- Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
- Failure to give informed consent
- History of prolonged QT interval or a history of clinically significant arrhythmia
- Age < than 18 years
- Pregnancy or nursing
- Use of narcotics more than 3 days per week
- Uncontrolled high blood pressure
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
The hypothesis of this pilot study is that nVNS will result in relief of nausea by modulation of vagal nerve activity. nVNS is the first non-invasive, handheld medical device applied on the side of the neck and sends gentle, patented mild electrical stimulation through the skin to activate the vagus nerve. nVNS offers a potential alternative to Gastric electrical stimulation (GES) that could eliminate significant risks of injury or illness or identify likely responders to implantable neurostimulator including implanted VNS (iVNS). nVNS could provide a more effective and safer alternative to the use of traditional rescue medications.
The group in the trial
- nVNS deviceTreatment being tested
Candidates who, after the screening period are eligible to receive the nVNS device.
Treatment: nVNS (gammaCore)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Non-invasive Vagal Nerve Stimulation Decreases the Need for Rescue Medication for Nausea Exacerbation in Patients with Chronic Nausea and Vomiting.Digestive diseases and sciences, 2026
- Record updated
- 15 October 2024